SLC5A2 and type 2 diabetes mellitus: Among these, sodium–glucose cotransporter-2 (SGLT2) inhibitors are recommended by the American Diabetes Association (ADA) as the preferred treatment option for patients with type 2 diabetes mellitus (T2D) who are also affected by atherosclerotic cardiovascular disease, heart failure, or kidney disease [2].